Literature DB >> 32483088

Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity.

Panagiotis Kourkoulis1, George Michalopoulos1, Hector Katifelis2, Ioanna Giannopoulou3, Andreas C Lazaris3, Ioannis Papaconstantinou4, George Karamanolis4, Maria Gazouli2.   

Abstract

OBJECTIVE: The LRG, HMGB1, MMP3 and ANXA1 proteins have been implicated in different inflammatory pathways in ulcerative colitis (UC), but their role as specific biomarkers of both endoscopic and histological activity has yet to be elucidated. In the present study, we aimed to evaluate the LRG1, HMGB1, MMP3 and ANXA1 as potential serum biomarkers for UC endoscopic and histological activity.
METHODS: This cross-sectional study included UC patients under 5-ASA, and healthy controls (HC) undergoing colonoscopy. Blood and biopsy samples were obtained and endoscopic Mayo sub-score (Ms) was recorded for the UC patients. Intramucosal calprotectin as a marker of histologic activity was evaluated in all biopsy samples and serum LRG1, HMGB1, MMP3 and ANXA1 levels were measured in the blood samples.
RESULTS: The HCs ANXA1 level was lower compared to that of the UC group [P = 0.00, area under the curve (AUC) = 0.881] and so was the HCs MMP3 level compared to that of patients (P = 0.00, AUC = 0.835). The HCs ANXA1 levels were also lower compared to these of the independent Ms groups, even to the Ms = 0 (P = 0.00, AUC = 0.913). UC endoscopic activity was associated with MMP3 levels (r = 0.54, P = 0.000) but not with ANXA1, LRG1 and HMGB1 levels
CONCLUSION: Serum ANXA1 is a potential diagnostic biomarker of UC and serum MMP3 is a potential biomarker of UC endoscopic and histological activity.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32483088     DOI: 10.1097/MEG.0000000000001783

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Small intestinal bacterial overgrowth and evaluation of intestinal barrier function in patients with ulcerative colitis.

Authors:  Chunchun Yang; Xueli Zhang; Suming Wang; Xiaohui Huo; Jing Wang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Fabrication and Evaluation of Celecoxib Oral Oleogel to Reduce the Inflammation of Ulcerative Colitis.

Authors:  Nermin M Sheta; Sylvia A Boshra
Journal:  AAPS PharmSciTech       Date:  2021-06-15       Impact factor: 3.246

3.  Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.

Authors:  Eriko Yasutomi; Toshihiro Inokuchi; Sakiko Hiraoka; Kensuke Takei; Shoko Igawa; Shumpei Yamamoto; Masayasu Ohmori; Shohei Oka; Yasushi Yamasaki; Hideaki Kinugasa; Masahiro Takahara; Keita Harada; Masaki Furukawa; Kouichi Itoshima; Ken Okada; Fumio Otsuka; Takehiro Tanaka; Toshiharu Mitsuhashi; Jun Kato; Hiroyuki Okada
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

Review 4.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.